Wrapmanager Inc. Sells 1,853 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Wrapmanager Inc. lowered its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 26.7% in the 3rd quarter, Holdings Channel reports. The firm owned 5,086 shares of the biopharmaceutical company’s stock after selling 1,853 shares during the period. Wrapmanager Inc.’s holdings in Halozyme Therapeutics were worth $291,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of HALO. US Bancorp DE raised its position in Halozyme Therapeutics by 64.6% in the 1st quarter. US Bancorp DE now owns 13,912 shares of the biopharmaceutical company’s stock worth $566,000 after buying an additional 5,458 shares during the last quarter. State Board of Administration of Florida Retirement System raised its holdings in shares of Halozyme Therapeutics by 9.2% during the first quarter. State Board of Administration of Florida Retirement System now owns 41,550 shares of the biopharmaceutical company’s stock valued at $1,587,000 after purchasing an additional 3,500 shares during the last quarter. Orion Portfolio Solutions LLC lifted its position in Halozyme Therapeutics by 19.5% during the first quarter. Orion Portfolio Solutions LLC now owns 35,534 shares of the biopharmaceutical company’s stock valued at $1,446,000 after purchasing an additional 5,809 shares during the period. Covestor Ltd boosted its holdings in Halozyme Therapeutics by 134.5% in the first quarter. Covestor Ltd now owns 2,573 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 1,476 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC grew its position in Halozyme Therapeutics by 4.6% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 12,067 shares of the biopharmaceutical company’s stock worth $491,000 after purchasing an additional 536 shares during the period. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Trading Up 5.3 %

Shares of NASDAQ:HALO opened at $44.81 on Wednesday. The company has a market cap of $5.70 billion, a PE ratio of 14.84, a price-to-earnings-growth ratio of 0.42 and a beta of 1.29. Halozyme Therapeutics, Inc. has a 12-month low of $33.15 and a 12-month high of $65.53. The stock has a 50 day moving average of $55.42 and a 200 day moving average of $53.53. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on HALO. Wells Fargo & Company cut Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price target for the company from $58.00 to $62.00 in a report on Monday, October 7th. Benchmark reissued a “buy” rating and issued a $60.00 target price on shares of Halozyme Therapeutics in a report on Thursday, August 8th. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price objective for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. Finally, Morgan Stanley boosted their target price on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $61.11.

Insider Activity

In related news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $59.09, for a total transaction of $590,900.00. Following the completion of the transaction, the chief executive officer now directly owns 676,744 shares of the company’s stock, valued at approximately $39,988,802.96. This trade represents a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 60,000 shares of company stock worth $3,425,000 in the last three months. Company insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.